Wernicke-Korsakoff syndrome associated with mtDNA disease.

Abstract:

Introduction:Wernicke encephalopathy (WE) and Wernicke-Korsakoff syndrome (WKS) are well-known disorders caused by thiamine deficiency. In addition to the classical concept of these diseases, some literature data suggest a connection between mitochondrial dysfunction and WE/WKS. Psychotic disorders and WKS seem to run in families, as the deficiency of the oxidative phosphorylation can be a trigger factor in psychotic events and WE/WKS as well. We present a patient harbouring the m.A3243G mtDNA mutation with the clinical and magnetic resonance imaging (MRI) findings of WKS who developed schizophrenia with predominantly negative symptoms some years later. Case presentation:A 27-year-old woman was referred to our clinic with severe weight loss after severe vomiting episodes, memory dysfunction and gait ataxia. Family history, as well as clinical, imaging and laboratory findings suggested a mitochondrial aetiology of her symptoms. Brain MRI detected bilateral mild thalamic lesions and loss of corpus mammillae, indicating Wernicke encephalopathy. Genetic testing detected an m.A3243G mtDNA mutation, which has been frequently associated with mitochondrial encephalopathy with lactic acidosis and stroke-like episodes. High-dose vitamin B1 supplementation with supportive antioxidant therapy improved the patient's memory and learning disturbance; however, some months later she developed psychosis with predominantly negative symptoms and her cognitive functions deteriorated again. Both cognitive and negative symptoms responded well to cariprazine monotherapy. Discussion:Mitochondrial disease due to mtDNA alteration can be a rare cause of WE. In addition to vitamin B1 supplementation, cariprazine with significant dopamine D3 receptor binding can be useful to treat the predominantly negative symptoms and cognitive dysfunction in patients with mitochondrial dysfunction. Conclusion:We assume that patients with a mitochondrial disorder might be prone to develop WE/WKS and therefore need tailored supportive therapy during metabolic crisis as well as symptom-based personalized antipsychotic treatment.

journal_name

Ther Adv Neurol Disord

authors

Jimoh IJ,Sebe B,Balicza P,Fedor M,Pataky I,Rudas G,Gal A,Inczedy-Farkas G,Nemeth G,Molnar MJ

doi

10.1177/1756286420938972

subject

Has Abstract

pub_date

2020-07-30 00:00:00

pages

1756286420938972

eissn

1756-2856

issn

1756-2864

pii

10.1177_1756286420938972

journal_volume

13

pub_type

  • Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.

    abstract::For patients with relapsing-remitting multiple sclerosis (RRMS), there are currently six approved medications that have been shown to alter the natural course of the disease. The approved medications include three beta interferon formulations, glatiramer acetate, natalizumab and mitoxantrone. Treating aggressive forms...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285609344375

    authors: Awad A,Stüve O

    更新日期:2009-11-01 00:00:00

  • Autoimmune glial fibrillary acidic protein astrocytopathy with lesions distributed predominantly in the entire spinal cord.

    abstract::Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy has been considered a novel central nervous system autoimmune disease characterized by relapse and responsiveness to corticosteroid with a specific GFAP-Immunoglobulin G (IgG) being noted in cerebrospinal fluid. We report the case of a 21-year-old girl p...

    journal_title:Therapeutic advances in neurological disorders

    pub_type:

    doi:10.1177/1756286420909973

    authors: Li XL,Han J,Zhao HT,Long YM,Zhang BW,Wang HY

    更新日期:2020-06-03 00:00:00

  • Diagnosis and treatment of impulse control disorders in patients with movement disorders.

    abstract::Impulse control disorders are a psychiatric condition characterized by the failure to resist an impulsive act or behavior that may be harmful to self or others. In movement disorders, impulse control disorders are associated with dopaminergic treatment, notably dopamine agonists (DAs). Impulse control disorders have b...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285613476127

    authors: Mestre TA,Strafella AP,Thomsen T,Voon V,Miyasaki J

    更新日期:2013-05-01 00:00:00

  • Intracranial aneurysms: optimized diagnostic tools call for thorough interdisciplinary treatment strategies.

    abstract:OBJECTIVE:Intracranial aneurysms (IAs) require deliberately selected treatment strategies as they are incrementally found prior to rupture and deleterious subarachnoid haemorrhage (SAH). Multiple and recurrent aneurysms necessitate both neurointerventionalists and neurosurgeons to optimize aneurysmal occlusion in an in...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285611415309

    authors: Mueller OM,Schlamann M,Mueller D,Sandalcioglu IE,Forsting M,Sure U

    更新日期:2011-09-01 00:00:00

  • Can inflammation be resolved in Alzheimer's disease?

    abstract::Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss and dementia. Accumulating evidence suggests that inflammation is involved in the pathogenesis of AD. Epidemiological studies suggest that use of anti-inflammatory drugs is associated with a lower incidence of AD. However,...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286418791107

    authors: Zhu M,Wang X,Sun L,Schultzberg M,Hjorth E

    更新日期:2018-08-09 00:00:00

  • Percutaneous transluminal angioplasty and stenting for symptomatic intracranial arterial stenosis: a systematic review and meta-analysis.

    abstract:OBJECTIVES:The cumulative safety and efficacy measures of percutaneous transluminal angioplasty and stenting (PTAS) for secondary stroke prevention in patients with symptomatic intracranial arterial stenosis (sICAS) have not previously been evaluated using a meta-analytical approach. METHODS:We conducted a systematic ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285616650357

    authors: Tsivgoulis G,Katsanos AH,Magoufis G,Kargiotis O,Papadimitropoulos G,Vadikolias K,Karapanayiotides T,Ellul J,Alexandrov AW,Mitsias PD,Alexandrov AV

    更新日期:2016-09-01 00:00:00

  • An update on the treatment of Sydenham's chorea: the evidence for established and evolving interventions.

    abstract::Over 320 years after Thomas Sydenham described the condition labelled Sydenham's chorea, it remains poorly understood. The disorder is an antineuronal antibody-mediated neuropsychiatric disorder caused by a poststreptococcal, autoimmune condition affecting control of movement, mood, behaviour and potentially the heart...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285610382063

    authors: Walker KG,Wilmshurst JM

    更新日期:2010-09-01 00:00:00

  • Application of immunotherapy for neurological manifestations in hypermobile Ehlers-Danlos syndrome.

    abstract::Ehlers-Danlos syndrome (EDS) is a heterogeneous heritable connective tissue disorder with various neurological manifestations, including chronic pain. The neurological manifestations in EDS are often regarded as being caused by the associated musculoskeletal disorders or polyneuropathy. Here, we present two patients w...

    journal_title:Therapeutic advances in neurological disorders

    pub_type:

    doi:10.1177/1756286418793766

    authors: Araki M,Lin Y,Ono H,Sato W,Yamamura T

    更新日期:2018-08-18 00:00:00

  • Role of immune responses for extracellular matrix remodeling in the ischemic brain.

    abstract::Neuroinflammation is one of the key components contributing to the devastating outcome of ischemic stroke. Starting with stroke onset, inflammatory processes contribute both to cell damage and tissue remodeling. The early release of alarmins triggers the upregulation of multiple proinflammatory cytokines, resulting in...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286418818092

    authors: Dzyubenko E,Manrique-Castano D,Kleinschnitz C,Faissner A,Hermann DM

    更新日期:2018-12-17 00:00:00

  • Current and future treatments for Alzheimer's disease.

    abstract::Alzheimer's dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three choline...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285612461679

    authors: Yiannopoulou KG,Papageorgiou SG

    更新日期:2013-01-01 00:00:00

  • Neutralizing antibodies against interferon-Beta.

    abstract::The development of neutralizing antibodies (NAbs) is a major problem in multiple sclerosis (MS) patients treated with interferon-beta (IFN-ß). Whereas binding antibodies (BAbs) can be demonstrated in the vast majority of patients, only a smaller proportion of patients develop NAbs. The principle in NAb in vitro assays...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285608095144

    authors: Sorensen PS

    更新日期:2008-09-01 00:00:00

  • Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment.

    abstract::Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system. Demyelinization of nerve fibres not only affects the motor and sensory systems functionally, but may also cause psychopathological signs and symptoms. In addition to the psychiatric manifestations of MS, many patients have reacti...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285608100325

    authors: Haussleiter IS,Brüne M,Juckel G

    更新日期:2009-01-01 00:00:00

  • Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.

    abstract::The BEtaferon®/BEtaseron® in Newly Emerging MS For Initial Treatment (BENEFIT) trial assessed the efficacy of early versus delayed treatment with interferon beta-1b for patients with clinically isolated syndrome (CIS). Patients were randomly assigned to receive either interferon beta-1b 250 μg every other day (early t...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285614549554

    authors: Freedman MS

    更新日期:2014-11-01 00:00:00

  • Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data.

    abstract:BACKGROUND:The aim of this study was to analyse registry data of seizure outcome and adverse events (AEs) for perampanel as add-on therapy in patients with focal epilepsy since its approval in 2012 for adjunctive treatment of focal epilepsy in patients ⩾12 years. METHOD:A retrospective 2-year chart review of all patie...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285616661115

    authors: Rohracher A,Kalss G,Leitinger M,Granbichler C,Deak I,Dobesberger J,Kuchukhidze G,Thomschewski A,Höfler J,Trinka E

    更新日期:2016-11-01 00:00:00

  • Paradoxical association of symptomatic cerebral edema with local hypoperfusion caused by the 'watershed shift' after revascularization surgery for adult moyamoya disease: a case report.

    abstract::Superficial temporal artery-middle cerebral artery anastomosis is generally considered as an effective method in improving damage associated with intracerebral occlusions in moyamoya disease. Hemodynamic changes caused by revascularization are the cause of many postoperative complications. Of the 186 consecutive surge...

    journal_title:Therapeutic advances in neurological disorders

    pub_type:

    doi:10.1177/1756286419878343

    authors: Yu J,Hu M,Yi L,Zhou K,Zhang J,Chen J

    更新日期:2019-09-25 00:00:00

  • Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials.

    abstract:Background:Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares data also for the prophylaxis of cluster headache. Objective:To p...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286420918088

    authors: Gklinos P,Mitsikostas DD

    更新日期:2020-04-28 00:00:00

  • Advances in brain imaging in multiple sclerosis.

    abstract::Brain imaging is increasingly used to support clinicians in diagnosing multiple sclerosis (MS) and monitoring its progression. However, the role of magnetic resonance imaging (MRI) in MS goes far beyond its clinical application. Indeed, advanced imaging techniques have helped to detect different components of MS patho...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286419859722

    authors: Cortese R,Collorone S,Ciccarelli O,Toosy AT

    更新日期:2019-06-27 00:00:00

  • Hypothalamic deep brain stimulation in the treatment of chronic cluster headache.

    abstract::Cluster headache (CH) is a short-lasting unilateral headache associated with ipsilateral craniofacial autonomic manifestations. A positron emission tomography (PET) study has shown that the posterior hypothalamus is activated during CH attacks, suggesting that hypothalamic hyperactivity plays a key role in CH pathophy...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285610370722

    authors: Leone M,Franzini A,Cecchini AP,Broggi G,Bussone G

    更新日期:2010-05-01 00:00:00

  • Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction.

    abstract:OBJECTIVES:To assess clinical outcomes and patient satisfaction in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN) who were switched from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG). METHODS:Eight consecutive patients, four...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285614563056

    authors: Hadden RD,Marreno F

    更新日期:2015-01-01 00:00:00

  • Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial.

    abstract:BACKGROUND:Efficacy of interferon beta in multiple sclerosis (MS) can be dampened in patients who develop neutralizing antidrug antibodies (NAbs). Peginterferon beta1a is an interferon conjugated with a polyethylene glycol (PEG) moiety. Pegylation increases a drug's half life and exposure, and may also reduce immunogen...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285616633967

    authors: White JT,Newsome SD,Kieseier BC,Bermel RA,Cui Y,Seddighzadeh A,Hung S,Crossman M,Subramanyam M

    更新日期:2016-07-01 00:00:00

  • Vascular medicine and thrombectomy in stroke.

    abstract::The treatment of stroke caused by intracranial vessel occlusion with intravenous recombinant tissue plasminogen activator (rt-PA) was the only evidence-based treatment option for a long time. Nevertheless the response rate was disappointing in large vessel occlusions. Five studies that evaluated the efficacy of mechan...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285617742082

    authors: Fischer S,Weber W

    更新日期:2017-11-22 00:00:00

  • Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE).

    abstract:Background:Gastrointestinal (GI) events are common adverse events (AEs) associated with delayed-release dimethyl fumarate (DMF), an approved treatment for relapsing-remitting multiple sclerosis (RRMS). The objective of the TOLERATE study was to evaluate GI tolerability and GI mitigation via symptomatic therapies in pat...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286418768775

    authors: Gold R,Schlegel E,Elias-Hamp B,Albert C,Schmidt S,Tackenberg B,Xiao J,Schaak T,Salmen HC

    更新日期:2018-04-18 00:00:00

  • Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis.

    abstract:Background:No evidence of disease activity (NEDA) is a composite measurement, incorporating clinical and magnetic resonance imaging (MRI) elements of disease activity to sensitively evaluate the therapeutic efficacy of treatments for relapsing-remitting multiple sclerosis (RRMS). Objective:To assess the NEDA status of...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286418795085

    authors: Arnold DL,Shang S,Dong Q,Meergans M,Naylor ML

    更新日期:2018-08-28 00:00:00

  • Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: towards clinical integration?

    abstract:Background:Whole brain atrophy (WBA) estimates in multiple sclerosis (MS) correlate more robustly with clinical disability than traditional, lesion-based metrics. We compare Structural Image Evaluation using Normalisation of Atrophy (SIENA) with the icobrain longitudinal pipeline (icobrain long), for assessment of long...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286418823462

    authors: Beadnall HN,Wang C,Van Hecke W,Ribbens A,Billiet T,Barnett MH

    更新日期:2019-01-25 00:00:00

  • Web-based interventions in multiple sclerosis: the potential of tele-rehabilitation.

    abstract::The World Wide Web is increasingly used in therapeutic settings. In this regard, internet-based interventions have proven effective in ameliorating several health behaviors, amongst them physical activity behavior. Internet-delivered interventions have shown positive effects on physical activity and physical function ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285616640684

    authors: Tallner A,Pfeifer K,Mäurer M

    更新日期:2016-07-01 00:00:00

  • Inflammatory molecules might become both biomarkers and therapeutic targets for stroke management.

    abstract::Stroke is the fifth leading cause of death and the most frequent cause of disability worldwide. Currently, stroke diagnosis is based on neuroimaging; therefore, the lack of a rapid tool to diagnose stroke is still a major concern. In addition, therapeutic approaches to combat ischemic stroke are still scarce, since th...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286418789340

    authors: Ramiro L,Simats A,García-Berrocoso T,Montaner J

    更新日期:2018-08-06 00:00:00

  • Therapy with cladribine is efficient and safe in patients previously treated with natalizumab.

    abstract:Background:The humanized anti-α4 integrin monoclonal antibody natalizumab has proven to be very effective in patients with highly active relapsing-remitting multiple sclerosis (MS), but harbors the risk of progressive multifocal leukoencephalopathy (PML). Recently, new therapeutic options have become available for pati...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286419887596

    authors: Möhn N,Skripuletz T,Sühs KW,Menck S,Voß E,Stangel M

    更新日期:2019-12-02 00:00:00

  • Advances in spinal muscular atrophy therapeutics.

    abstract::Spinal muscular atrophy (SMA) is a progressive, recessively inherited neuromuscular disease, characterized by the degeneration of lower motor neurons in the spinal cord and brainstem, which leads to weakness and muscle atrophy. SMA currently represents the most common genetic cause of infant death. SMA is caused by th...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285618754501

    authors: Parente V,Corti S

    更新日期:2018-02-05 00:00:00

  • Effective and safe diet therapies for Lennox-Gastaut syndrome with mitochondrial dysfunction.

    abstract:Background:Lennox-Gastaut syndrome (LGS) is a typical intractable form of epilepsy that most often occurs between the second and sixth year of life. This study aimed to evaluate the clinical efficacy and safety of ketogenic diet therapies (DTs) for LGS with mitochondrial dysfunction. Methods:This was a retrospective s...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286419897813

    authors: Na JH,Kim HD,Lee YM

    更新日期:2020-02-06 00:00:00

  • The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.

    abstract::B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and production of autoantibodies directed against myelin. Hence, the usage of B-cell-depleting monoclonal antibodies as therapy for autoimmune...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285615601933

    authors: Sorensen PS,Blinkenberg M

    更新日期:2016-01-01 00:00:00